GlaxoSmithKline and developing country access to essential medicines (A
Publication Year
2005
Abstract
The merger of GlaxoWellcome and SmithKlineBeecham in 2000 created the world’s second largest pharmaceutical company, GlaxoSmithKline (GSK). GSK also became the world’s leader in the provision of drugs to treat the three most critical diseases in the developing world: HIV/AIDS, malaria and tuberculosis. In addition to merger related strategy and restructuring activities, the company finds itself having to respond to pressures to increase access to these essential medicines in developing countries, including the possibility of major reductions in price. How should GSK respond to these pressures?
Topic List
Corporate social responsibility, Stakeholders, Pricing, Pharmaceutical industry, Access to medicines, Leadership, Developing countries
Publication Research Centre
Centre for Marketing
Available on ECCH
No
